ROSEMONT, Ill., Sept. 30, 2026 (GLOBE NEWSWIRE) — Wintrust Financial Corporation (“Wintrust”) (Nasdaq: WTFC) today announced it will release third quarter and year-to-date 2026 earnings results after the market closes on Monday, October 19, 2026, and host a conference call on Tuesday, October 20, 2026, at 10:00 a.m. CDT. 

For individuals wanting to listen to a simultaneous audio-only web cast, this may be accessed at Webcast Link.

Individuals interested in participating in the call by addressing questions to management should register for the call at Conference Call Link to receive a dial-in number and unique PIN to access the call seamlessly. It is recommended that you join 10 minutes prior to the event start (although you may register and dial in at any time during the call).

An accompanying slide presentation will be available on the Company’s website at www.wintrust.com, Investor Relations link.

A replay of the audio-only webcast and an accompanying slide presentation will subsequently be available at www.wintrust.com, Investor Relations, News & Events, Events & Presentations link.   The text of the third quarter and year-to-date 2026 earnings release will be available at www.wintrust.com, Investor Relations, News & Events, News link.

About Wintrust

Wintrust is a financial holding company with approximately $75 billion in assets whose common stock is traded on the NASDAQ Global Select Market. Guided by its “Different Approach, Better Results” philosophy, Wintrust offers the sophisticated resources of a large bank while providing a community banking experience to each customer. Wintrust operates more than 200 retail banking locations through 16 community bank subsidiaries in the greater Chicago, southern Wisconsin, west Michigan, northwest Indiana, and southwest Florida market areas. In addition, Wintrust operates various non-bank business units, providing residential mortgage origination, wealth management, commercial and life insurance premium financing, short-term accounts receivable financing/outsourced administrative services to the temporary staffing services industry, and qualified intermediary services for tax-deferred exchanges. For more information, please visit www.wintrust.com.

Forward-Looking Information

This press release contains forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that such statements are predictions and that actual events or results may differ materially. Wintrust’s expected financial results or other plans are subject to a number of risks and uncertainties. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see “Risk Factors” and the forward-looking statement disclosure contained in Wintrust’s Annual Report on Form 10-K for the most recently ended fiscal year and in Wintrust’s subsequent Quarterly Reports on Form 10-Q. Forward-looking statements speak only as of the date made and Wintrust undertakes no duty to update the information.

FOR MORE INFORMATION CONTACT:
David A. Dykstra, Vice Chairman & Chief Operating Officer
(847) 939-9000
Amy Yuhn, Executive Vice President, Communications
(847) 939-9591
Website address: www.wintrust.com

LAFOX, Ill., Sept. 30, 2026 (GLOBE NEWSWIRE) — Richardson Electronics, Ltd. (NASDAQ: RELL) plans to release its financial results for its first quarter ended August 29, 2026 after the close of business on Wednesday, October 7, 2026. The release will be distributed by GlobeNewswire and will be available on the Company’s website at www.rell.com.

On Thursday, October 8, 2026, at 9:00 a.m. Central Time, Edward J. Richardson, Chairman and Chief Executive Officer, and Robert J. Ben, Chief Financial Officer, will host a conference call to discuss the Company’s first quarter fiscal year 2027 results. A question-and-answer session will be included as part of the call’s agenda.

Participant Instructions

Participants may register for the call here. While not required, it is recommended you join 10 minutes prior to the event start. A replay of the call will be available beginning at 1:00 p.m. Central Time on October 8, 2026, for seven days. Registration instructions are also on our website at www.rell.com.

In addition, the webcast link is available here.

About Richardson Electronics, Ltd.

Richardson Electronics, Ltd. is a leading global manufacturer of engineered solutions, green energy products, power grid and microwave tubes, and related consumables; power conversion and RF and microwave components including green energy solutions; tubes for diagnostic imaging equipment; and customized display solutions.

More than 55% of our products are manufactured in LaFox, Illinois, Marlborough, Massachusetts, or Donaueschingen, Germany, or by one of our manufacturing partners throughout the world. All our partners manufacture to our strict specifications and per our Supplier Code of Conduct. We serve customers in alternative energy, healthcare, aviation, broadcast, communications, industrial, marine, medical, military, scientific, and semiconductor markets. The Company’s strategy is to provide specialized technical expertise and “engineered solutions” based on our core engineering and manufacturing capabilities. The Company provides solutions and adds value through design-in support, systems integration, prototype design and manufacturing, testing, logistics, and aftermarket technical service and repair through its global infrastructure. More information is available at www.rell.com.

Richardson Electronics’ common stock trades on the NASDAQ Global Select Market under the ticker symbol RELL.

For Details Contact:   40W267 Keslinger Road
Edward J. Richardson Robert Ben PO BOX 393
Chairman and CEO EVP & CFO LaFox, IL 60147-0393 USA
Phone: (630) 208-2320 (630) 208-2203 (630) 208-2200 | Fax: (630) 208-2550
     

Appointment Is Part of ACI’s Effort to Strengthen AI Readiness, Resilience, and Deployment

SAN JOSE, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) — California Water Service Group (NYSE:CWT) announced today that its Chairman & Chief Executive Officer, Martin A. Kropelnicki, has joined the Alliance for Critical Infrastructure (ACI) Board of Directors.

Kropelnicki’s appointment is part of ACI’s effort to bring together leading companies in communications, energy, financial services, information technology, transportation, and water to strengthen the country’s physical and cyber resilience and address the unique and significant risks and opportunities posed by the emergence of AI.

“We are on the precipice of technological change that is unlike anything we’ve seen before, and it is essential that we work together to identify vulnerabilities, develop protective strategies, advance smart public policy, and share best practices, both within ACI and beyond to all operators of critical infrastructure in America,” Kropelnicki said. “I am pleased to serve on ACI’s Board because I am committed to contributing to efforts to keep my customers’—and our nation’s—water systems safe.”

The expansion of ACI builds upon a foundation of over a decade of private-sector national security work in collaboration with the government and serves as confirmation of the vision of ACI’s nine founding members. For more information, visit https://criticalalliance.org.

California Water Service Group is the parent company of regulated utilities Cal Water, Hawaii Water Service, New Mexico Water Service and Washington Water Service, as well as Texas Water Service (TWSC, Inc.), a utility holding company. Together, these companies provide regulated and non-regulated water and wastewater service to more than 2.2 million people in California, Hawaii, New Mexico, Washington, and Texas. Group’s common stock trades on the New York Stock Exchange under the symbol “CWT.” Additional information is available online at www.calwatergroup.com.

CONTACT: Shannon Dean, (408) 367-8243

SAN DIEGO, Sept. 30, 2026 (GLOBE NEWSWIRE) — American Assets Trust, Inc. (NYSE:AAT) (the “Company”) will announce its third quarter 2026 earnings in a press release to be issued after the market closes on Tuesday, October 27, 2026.

Senior management will hold a conference call for its third quarter 2026 earnings on Wednesday, October 28, 2026 at 8:00 a.m. Pacific Time (“PT”).

To access the conference call, please dial 1 (833) 816-1162 and ask to join the American Assets Trust, Inc. Conference Call.

A live audio webcast of the conference call will be available on the “Investor Relations” section of the Company’s website at www.americanassetstrust.com. A replay webcast will be available on the Company’s website approximately one hour after the conclusion of the conference call.

About American Assets Trust, Inc.

American Assets Trust, Inc. is a full service, vertically integrated and self-administered real estate investment trust, or REIT, headquartered in San Diego, California. The Company has over 55 years of experience in acquiring, improving, developing and managing premier office, retail and residential properties throughout the United States in some of the nation’s most dynamic, high-barrier-to-entry markets primarily in Southern California, Northern California, Washington, Oregon, Texas and Hawaii. The Company’s office portfolio comprises approximately 4.3 million square feet, and its retail portfolio comprises approximately 2.4 million rentable square feet. In addition, the Company owns one mixed-use property (including approximately 94,000 rentable square feet of retail space and a 369-room all-suite hotel) and 2,302 multifamily units. In 2011, the Company was formed to succeed to the real estate business of American Assets, Inc., a privately held corporation founded in 1967 and, as such, has significant experience, long-standing relationships and extensive knowledge of its core markets, submarkets and asset classes. For additional information, please visit www.americanassetstrust.com.

Forward Looking Statements

This press release may contain forward-looking statements within the meaning of the federal securities laws, which are based on current expectations, forecasts and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. Forward-looking statements relate to expectations, beliefs, projections, future plans and strategies, anticipated events or trends and similar expressions concerning matters that are not historical facts. In some cases, you can identify forward-looking statements by the use of forward-looking terminology such as “may,” “will,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” or “potential” or the negative of these words and phrases or similar words or phrases which are predictions of or indicate future events or trends and which do not relate solely to historical matters. The following factors, among others, could cause actual results and future events to differ materially from those set forth or contemplated in the forward-looking statements: adverse economic or real estate developments in our markets; defaults on, early terminations of or non-renewal of leases by tenants, including significant tenants; decreased rental rates or increased vacancy rates; our failure to generate sufficient cash flows to service our outstanding indebtedness; fluctuations in interest rates and increased operating costs; our failure to obtain necessary outside financing; our inability to develop or redevelop our properties due to market conditions; investment returns from our developed properties may be less than anticipated; general economic conditions, including the impact of tariffs and other trade restrictions; the potential impact of a prolonged government shutdown; financial market fluctuations; risks that affect the general office, retail, multifamily and mixed-use environment; the competitive environment in which we operate; system failures or security incidents through cyberattacks; the impact of epidemics, pandemics, or other outbreaks of illness, disease or virus and the actions taken by government authorities and others related thereto, including the ability of our company, our properties and our tenants to operate; difficulties in identifying properties to acquire and completing acquisitions; our failure to successfully operate acquired properties and operations; risks related to joint venture arrangements; potential litigation; difficulties in completing dispositions; conflicts of interests with our officers or directors; lack or insufficient amounts of insurance; environmental uncertainties and risks related to adverse weather conditions and natural disasters; other factors affecting the real estate industry generally; limitations imposed on our business and our ability to satisfy complex rules in order for American Assets Trust, Inc. to continue to qualify as a REIT, for U.S. federal income tax purposes; and changes in governmental regulations or interpretations thereof, such as real estate and zoning laws and increases in real property tax rates and taxation of REITs. While forward-looking statements reflect the company’s good faith beliefs, assumptions and expectations, they are not guarantees of future performance. For a further discussion of these and other factors that could cause the company’s future results to differ materially from any forward-looking statements, see the section entitled “Risk Factors” in the company’s most recent annual report on Form 10-K, and other risks described in documents subsequently filed by the company from time to time with the Securities and Exchange Commission. The company disclaims any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, of new information, data or methods, future events or other changes.

Source: American Assets Trust, Inc.

Investor Contact:

American Assets Trust

Robert F. Barton
Executive Vice President and Chief Financial Officer
858-350-2607

Leader in targeted immuno-oncology drug development 
brings three decades of academic and biopharmaceutical oncology expertise

SOUTH SAN FRANCISCO, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced the appointment of David Raben, M.D., as Chief Medical Officer. Dr. Raben brings more than 30 years of experience in academic translational research, clinical care, and oncology drug development across the biopharmaceutical sector.

“David’s deep expertise in advancing innovative and targeted oncology therapies, alongside a proven track record of leading programs from early development through regulatory approval, will be important as we advance PLN-101095,” said Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer of Pliant. “We look forward to David’s leadership and insight as we progress toward key trial readouts in 2027.”

Dr. Raben is a board-certified radiation oncologist and a nationally recognized clinical expert in head and neck, lung, and genitourinary cancers. Most recently, he served as Chief Medical Officer at Bicara Therapeutics. At Bicara, Dr. Raben oversaw clinical development of the company’s first-in-class lead asset, ficerafusp alfa (BCA101), across multiple indications and stages of development, and led clinical strategy for their bifunctional antibody platform. Prior to this Dr. Raben was Vice President of Global Product Development and Product General Manager for Oncology at Amgen, where he led strategy and clinical execution for the anti-DLL3 program in neuroendocrine cancers. Earlier, as Vice President and Franchise Leader for Oncology Clinical Development at Genentech, Dr. Raben oversaw late-stage precision medicine and immunotherapy programs in head and neck, skin and thoracic cancers. Before moving to industry, Dr. Raben spent more than 20 years as a professor at the University of Colorado Cancer Center, where his research combined novel biologic therapies with radiation for patients with locally advanced head and neck and lung cancers with his translational work spanning EGFR signaling, DNA damage repair, TGF-β, and checkpoint inhibition. Dr. Raben served for over 15 years on the NRG Oncology Head and Neck Cancer Steering Committee, co-founded the NRG Radiation Developmental Therapeutics Committee, and co-led the SWOG-Genitourinary (GU) Committee’s prostate cancer subcommittee. Dr. Raben earned his B.A. from Duke University and his M.D. from Bowman Gray School of Medicine at Wake Forest University and completed his residency in radiation oncology at The Johns Hopkins Hospital.

About Pliant Therapeutics, Inc.

Pliant Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of integrin-based therapeutics. Pliant’s lead program is PLN-101095, a small molecule, dual-selective inhibitor of αvß8 and αvß1 integrins, that is being developed for the treatment of ICI-refractory advanced or metastatic solid tumors. PLN-101095 is being investigated in FORTIFY, a Phase 1b indication expansion trial enrolling patients with NSCLC, tumors with high tumor mutational burden or clear cell renal cell carcinoma. Pliant’s preclinical research is focused on tissue-specific delivery and internalization of drug payloads utilizing integrin receptor-binding molecules with programs focused on delivering siRNAs to skeletal muscle cells, adipocytes, and renal cells. For additional information, please visit: www.PliantRx.com. Follow Pliant on social media at X, LinkedIn and Facebook.

Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

In connection with the commencement of Dr. Raben’s employment with the Company on September 30, 2026 (the “Grant Date”), the Company granted him non-statutory stock options to purchase an aggregate of 575,000 shares of Company common stock (the “Inducement Grant”). The Inducement Grant was granted under the Company’s 2022 Inducement Plan (the “Plan”) and is subject to the terms and conditions of the Plan. The Inducement Grant was granted as an inducement material to Dr. Raben entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Grant has an exercise price per share that is equal to the closing price of the Company’s common stock on the Grant Date. The Inducement Grant will vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of Dr. Raben’s start date, and thereafter the remainder of the shares vest in 36 equal monthly installments, subject to Dr. Raben’s continued employment with the Company through the applicable vesting dates.

Investor and Media Contact:
Christopher Keenan
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.
ir@pliantrx.com  

Abivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026

Four oral presentations and three posters build upon Phase 3 ABTECT Maintenance and Induction programs in ulcerative colitis, long-term Phase 2 findings, and preclinical anti-fibrotic research

PARIS, France – September 30, 2026 – 10:05 PM CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced that seven scientific abstracts on obefazimod, its lead drug candidate for the treatment of moderately to severely active ulcerative colitis (UC), will be presented at the United European Gastroenterology (UEG) Week 2026 meeting, taking place October 17–20, 2026, in Barcelona, Spain. These presentations will highlight data from the Phase 3 ABTECT Maintenance and Induction trials in UC, long-term follow-up from the Phase 2 program in UC, and preclinical research on obefazimod’s anti-fibrotic and anti-tumor activity.

“The data being presented at UEG Week add to the growing understanding of obefazimod and its potential in inflammatory bowel disease,” said Marc de Garidel, MBA, Chief Executive Officer of Abivax. “These findings reinforce our confidence in obefazimod’s potential to address significant unmet needs for patients living with inflammatory bowel disease.”

Chris Rabbat, PhD, Chief Medical Officer of Abivax, added, “The seven accepted abstracts reflect the breadth and maturity of the obefazimod program, spanning Phase 3 maintenance results, long-term Phase 2 efficacy and safety data, and preclinical findings on inflammation and fibrosis. We look forward to sharing these findings with the global gastroenterology community and highlighting the growing clinical and scientific evidence supporting obefazimod.”

Visit the publications page of Abivax’s website to view the presentations after the conclusion of the meeting.

Data to be Presented:

Date & Time Session Room Abstract # Title Presenter
Oral Presentation
October 19, 10:50–11:00 Hot Topics in Clinical GI Research D3 OP097 Efficacy and safety of obefazimod in patients with moderately to severely active ulcerative colitis: results from the Phase 3, randomized, double-blind, placebo-controlled, 44-week maintenance trial (ABTECT-Maintenance) Prof. Bruce E. Sands, MD, MS

Professor of Medicine at Icahn School of Medicine at Mount Sinai

October 19, 10:50–11:00 Molecular Trajectories of Disease and Drug Responses in IBD A1 OP091 Obefazimod increases miR-124 expression to consistently modulate inflammation and fibrosis across preclinical models Prof. Silvio Danese, MD, PhD

Professor of Gastroenterology and Director of Gastroenterology and Gastrointestinal Endoscopy Unit at IRCCS San Raffaele Hospital

October 19, 12:00–12:10 Long-term Outcomes of Interventional Trials in IBD A2 OP107 Long-term efficacy and persistence with obefazimod after dose de-escalation to 25 mg: 3-year interim analysis in patients with moderately to severely active ulcerative colitis completing Week 144, stratified by prior advanced therapy experience: results from the Phase 2 program Prof. Bruce E. Sands, MD, MS

Professor of Medicine at Icahn School of Medicine at Mount Sinai

October 20, 12:20–12:30 Looking into the Future: Novel Therapeutics in IBD, Part 2 B3 OP260 Efficacy of obefazimod in Phase 3 ABTECT-Maintenance trial: results of 44-week therapy in subsets of patients with and without prior inadequate response to advanced therapies Prof. Silvio Danese, MD, PhD

Professor of Gastroenterology and Director of Gastroenterology and Gastrointestinal Endoscopy Unit at IRCCS San Raffaele Hospital

Moderated Poster
October 18, 17:24–17:30 Outcomes from RCT in IBD (II) Hall 7 – Poster Stage 2 MP0294 Efficacy, persistence, and safety of obefazimod in patients with moderately to severely active ulcerative colitis: 3-year interim analysis following dose de-escalation to 25 mg in the open-label maintenance Phase 2 study Bram Verstockt, MD, PhD

Associate Professor and Principal Investigator at KU Leuven

October 18, 17:36–17:42 Outcomes from RCT in IBD (II) Hall 7 – Poster Stage 2 MP0296 Symptoms of bowel urgency and nocturnal bowel movements are linked with improvement in clinical outcomes among patients with moderately to severely active ulcerative colitis treated with obefazimod: pooled results from the 8-week ABTECT Phase 3 induction trials David T. Rubin, MD

Professor of Medicine and Chief, Gastroenterology, Hepatology and Nutrition at The University of Chicago

E-Poster
October 17, 9:00 – 9:00 IBD, including microscopic colitis Hall 7 PP1180 Obefazimod reduces inflammation-driven tumor burden in a murine model of colitis-associated cancer Prof. Silvio Danese, MD, PhD

Professor of Gastroenterology and Director of Gastroenterology and Gastrointestinal Endoscopy Unit at IRCCS San Raffaele Hospital


About Abivax 

Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.

Contact:
Patrick Malloy
SVP, Investor Relations
Abivax SA
patrick.malloy@abivax.com
+1 847 987 4878

Media Contact:
LifeSci Communications
Karissa Baltz, PhD
Associate Director
LSC_ABIVAX@lifescicomms.com

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements, forecasts and estimates, including those relating to the Company’s business. Words such as “anticipate,” “expect,” “on track,” “potential,” “will” and variations of such words and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements concerning the potential therapeutic benefit of obefazimod and obefazimod’s potential to address significant unmet needs for patients living with inflammatory bowel disease, and other statements that are not historical fact. Although Abivax’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks, contingencies and uncertainties, many of which are difficult to predict and generally beyond the control of Abivax, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. A description of these risks, contingencies and uncertainties can be found in the documents filed by the Company with the French Autorité des Marchés Financiers pursuant to its legal obligations including its universal registration document (Document d’Enregistrement Universel) and in its Annual Report on Form 20-F for the fiscal year ended December 31, 2025 filed with the U.S. Securities and Exchange Commission on March 23, 2026, under the caption “Risk Factors.” These risks, contingencies and uncertainties include, among other things, the uncertainties inherent in research and development, future clinical data and analysis, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug candidate, as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of such product candidates, and the availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements. Special consideration should be given to the potential hurdles of clinical and pharmaceutical development, including further assessment by the Company and regulatory agencies and IRBs/ethics committees following the assessment of preclinical, pharmacokinetic, carcinogenicity, toxicity, CMC and clinical data. Furthermore, these forward-looking statements, forecasts and estimates are made only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Abivax disclaims any obligation to update these forward-looking statements, forecasts or estimates to reflect any subsequent changes that the Company becomes aware of, except as required by law. Information about pharmaceutical products (including products currently in development) that is included in this press release is not intended to constitute an advertisement. This press release is for information purposes only, and the information contained herein does not constitute either an offer to sell or the solicitation of an offer to purchase or subscribe for securities of the Company in any jurisdiction. Similarly, it does not give and should not be treated as giving investment advice. It has no connection with the investment objectives, financial situation or specific needs of any recipient. It should not be regarded by recipients as a substitute for exercise of their own judgment. All opinions expressed herein are subject to change without notice. The distribution of this document may be restricted by law in certain jurisdictions. Persons into whose possession this document comes are required to inform themselves about and to observe any such restrictions.

Attachment

ZUG, Switzerland, Sept. 30, 2026 (GLOBE NEWSWIRE) — Lithium Argentina AG (“Lithium Argentina” or the “Company”) (TSX: LAR) (NYSE: LAR) announced the results of a Scoping Study (the “Scoping Study”) for the Cauchari-Olaroz Stage 2 Expansion Project (“Stage 2” or the “Expansion Project”) in Jujuy Province, Argentina.

The Scoping Study supports a brownfield expansion designed to produce an additional 45,000 tonnes per annum (“tpa”) of lithium carbonate at Cauchari-Olaroz. The Scoping Study generated an after-tax NPV8% of $3.1 billion and IRR of 28.5% using a lithium carbonate price of $18,000/t.

Concurrently, the Company is proceeding with plans to accelerate an initial 10,000 tpa (the “Initial Phase”) of the planned 45,000 tpa Stage 2 expansion using adsorption Direct Lithium Extraction (“DLE”) technology, subject to receipt of applicable regulatory approvals and permits, including those required in connection with the procurement and deployment of certain technology and equipment. The initial module would provide an opportunity to accelerate incremental production, further demonstrate adsorption DLE performance on a commercial scale and support the phased development of Stage 2. This optionality allows the Company to continue optimizing process selection based on recovery, capital intensity, operating costs and execution considerations while leveraging the existing infrastructure and operating platform at Cauchari-Olaroz.

Highlights:

  • 45,000 tpa Lithium Carbonate Equivalent (“LCE”) Expansion: Stage 2 is designed to produce 45,000 tpa of LCE, increasing total Cauchari-Olaroz production capacity to approximately 85,000 tpa, with an expected 40-year operating life.
  • Compelling Economics: At $18,000/t lithium carbonate, after-tax NPV8% of $3.1 billion and IRR of 28.5%.
  • Competitive Cost Profile: Estimated operating costs of US$5,006/t of lithium carbonate, supported by higher process recoveries and brownfield synergies.
  • Flexible Hybrid DLE Processing: The characteristics of the Cauchari-Olaroz brine and existing infrastructure provide flexibility to optimize the processing approach based on cost, technical performance and environmental considerations.
  • Phased Development Approach:  Accelerated initial 10,000 tpa of the planned 45,000 tpa Stage 2 expansion using adsorption-based DLE technology, expected online during 2028, subject to permitting and regulatory approvals, including the required approvals in Argentina and China related to the deployment and transfer of the adsorption-based processing technology. The accelerated timing of this initial capacity is not reflected in the Scoping Study or its economic analysis.
  • Capital-Efficient Expansion: Initial capital cost of approximately US$1.0 billion, reflecting the advantages of expanding an established operating asset.
  • RIGI Approved: The project has received approval under Argentina’s Régimen de Incentivo para Grandes Inversiones (“RIGI”), providing long-term fiscal stability and investment incentives that enhance long-term project economics.
  • Financially Supported by Stage 1: The Company expects to fund Stage 2 through internally generated cash flow and project-level debt, leveraging the cash flow generation of the existing operation.

Sam Pigott, CEO of Lithium Argentina, commented:

“The Scoping Study confirms the significant value in expanding Cauchari-Olaroz, with an after-tax NPV of US$3.1 billion. Building on the strong performance of the existing operation, we will pursue a flexible, modular approach to Stage 2 development.

“We are moving immediately to advance a 10,000 tpa first phase using adsorption technology. It is the fastest and most capital-efficient path to incremental production, leveraging the existing infrastructure and permits, with a target for first production within two years.

“With RIGI approval secured and multiple funding pathways available, we have significant flexibility in how we advance Cauchari-Olaroz. More broadly, strong cash flow from the operation and the formation of the PPG joint venture position us to advance both of our core assets in parallel with our partners, with a disciplined focus on deploying capital where it generates the strongest returns for shareholders.”

A technical report, prepared by Golder Associates (“Golder”), in accordance with National Instrument 43-101 Standards of Disclosure for Mineral Projects (“NI 43-101”) and Subpart 1300 of Regulation S-K (“S-K 1300”), will be filed within 45 days. Unless otherwise indicated, all figures are in U.S. dollars and on a 100% basis.

Stage 2 Scoping Study Results – Summary1

Key Results  
Operating Profile  
Existing Capacity 40,000 tpa LCE
Scoping Study Expansion Annual Production under RIGI 45,000 tpa LCE
Total Cauchari-Olaroz Production Capacity after Expansion 85,000 tpa LCE
Scoping Study Expansion Project life 40 years
Processing Hybrid (SX) DLE
Economic Parameters2  
Lithium Carbonate Price $18,000 / t
NPV8% $3.1 B
IRR 28.5%
Payback 5 years
Financial Metrics  
Capital Costs $1.0 B
Initial Capital Intensity $22,530 / t
Operating Costs $5,006 / t
   

__________________________

1 All dollar figures are in United States dollars and are on a 100% basis unless otherwise indicated.
2 After-tax economic results.

Initial Phase Development Strategy 

The Scoping Study evaluates the economics of a single 45,000 tpa expansion.  The recovery method evaluated in the Scoping Study is based on brine pre-concentration followed by solvent extraction, and the capital costs, operating costs, production schedule and economic analysis presented have been developed on that basis. The Company intends to advance Stage 2 through a phased development strategy designed to reduce execution risk and advance the overall development plan. The Initial Phase will allow for an accelerated 10,000 tpa, leveraging existing infrastructure and permits.

Key elements of the Initial Phase include:

  • Permitting: The Company is advancing the required permitting and regulatory approvals for the Initial Phase, including the required approvals in Argentina and China related to the deployment and transfer of the adsorption-based processing technology. All required permits and regulatory approvals are currently targeted to be received during the first half of 2027.
  • Equipment supply: Engineering of the modular plant has commenced in China, which will subsequently be manufactured, shipped and assembled at the Cauchari-Olaroz site. Export of this technology from China is subject to Chinese regulatory authorization, which has not yet been obtained. Module engineering is proceeding in advance of receipt of this authorization.
  • Early works: Early-stage site works, including additional brine well development, activities that will also support the broader Stage 2 expansion, are underway to support the expansion Initial Phase.

Specific capital expenditure requirements for the Initial Phase will be available once detailed engineering is completed later this year, with the 2027 capex budget to be finalized accordingly. The capital required for the Initial Phase is not expected to increase the Scoping Study’s total estimated capital expenditure. The phased approach also preserves flexibility to pace the broader expansion in line with market conditions, while allowing the Initial Phase to satisfy the minimum investment requirements under RIGI.

The proposed accelerated development of the Initial Phase, including its capital requirements and development schedule, is not reflected in the Scoping Study or its economic analysis. 

Stage 2 Development Strategy 

The Scoping Study establishes a technically de-risked, industry-comparable economic base case for the full 45ktpa expansion using SX, a proven DLE technology available for study now. The Initial Phase reflects the Company’s preferred near-term execution path, selected for its cost and permitting advantages. These activities are expected to include additional production and exploration drilling, brine gathering and pipeline infrastructure, industrial water development and site preparation. Advancing this work alongside the initial module is expected to support the subsequent development of the remaining Stage 2 capacity.

The remaining 35,000 tpa of Stage 2 capacity will complete the expansion to 45,000 tpa, increasing total production capacity at Cauchari-Olaroz to approximately 85,000 tpa. The expansion is designed to integrate DLE capacity with the existing evaporation-based process, increasing lithium recovery while continuing to utilize the established evaporation ponds and lithium carbonate processing facilities.

The ability to expand adsorption technology beyond the Initial Phase of 10,000 tpa — for part or all of the remaining expansion — is contingent on further technical work, including demonstrating water consumption performance on a commercial scale and/or securing additional water resources. Adsorption has economic benefits, as well as a reduced footprint and water consumption performance will be assessed during operation of the Initial Phase of 10,000 tpa and is expected to help determine the applicability of adsorption technology for the balance of the expansion.

The Environmental Impact Assessment (“EIA”) application for the full 45,000 tpa expansion has been submitted, with environmental approval currently anticipated during 2027.

Operating Costs

Average life of project costs for the 45,000 tpa expansion are summarized below.

Operating Costs – Expansion Project ($ per tonne)
Category  
Reagents $1,734
Power & Energy $472
Labour $609
Maintenance $408
Salts harvesting & Disposal $776
G&A $213
Others $555
Sub-Total $4,768
Contingency $238
Total $5,006
   

Capital Costs

The capital cost for life of Stage 2 is estimated at $1.0 billion, inclusive of contingency, based on construction and are based on Argentine costs for labor and materials. This reflects a total capital intensity of approximately $22,500 per tonne of annual LCE production.

The estimated capital cost benefits from leveraging existing infrastructure, utilities and operating facilities at Cauchari-Olaroz are summarized below:

Capital Cost – Life of Project  ($ millions)
Wellfield, Ponds and Brine Systems $421
Processing Plants $356
Infrastructure/Power/TMA Costs $208
Owner Costs $28
Total Capital Costs (including contingency)3 $1,013
   

The Scoping Study contemplates a staged development underpinned by both existing site infrastructure and new process facilities. Wellfield, ponds and brine system infrastructure are largely related to the construction of these items. Plants capital costs include all the capital for the lithium plant, including: DLE plant, purification plant, utilities and LCE processing facilities.

Infrastructure, Power/Tailing Management Area (“TMA”) and energy costs relate to water supply, transformers, warehouse office buildings, camps, effluent plant, and waste yard infrastructure, power lines, fuel plant and emergency generation and salts disposal costs. 

__________________________

3 Initial capital costs include contingency applied by cost category.

RIGI

Stage 2 has received approval under RIGI. The Scoping Study incorporates the benefits associated with the approved RIGI framework, including enhanced fiscal stability, a reduced corporate income tax rate, accelerated depreciation and foreign exchange benefits, strengthening the project’s long-term economics.

Stage 2 Valuation Price Sensitivities and Returns

The financial results are derived from inputs based on an annual production schedule included in the Scoping Study with an incremental after-tax NPV8% of $3 billion. A sensitivity analysis of long-term lithium carbonate price on the economic results for the 45,000 tpa of LCE over a 40-year operating period is summarized below.

Key Parameters Scenario 1 Scenario 2
(Base Case)
Scenario 3
Lithium Carbonate Price $16,000/t $18,000/t $20,000/t
After-Tax NPV8% $2.5B $3.1B $3.7B
After-Tax IRR 25.3% 28.5% 31.4%
Payback (years) ~6 ~5 ~5
       

Mineral Resource

The January 2026 resource update supports Cauchari-Olaroz’ large-scale and high-quality lithium brine Deposit. Total M&I resources increased LCE estimates by 42% compared to the 2019 estimate, including a significant increase in Measured resources reflecting additional drilling, incorporation of operating data, increased resource area and basin-wide hydrogeological modeling. The improved geological and aquifer understanding strengthens confidence in the resource base and supports the Stage 2 expansion.

Mineral Resource Estimation 

The Mineral Resources for Stage 2 as described in the Scoping Study are summarized in the table below.

Resource Category Cauchari-Olaroz
Li (mg/L) LCE (Mt)
Measured 557 16.8
Indicated 571 11.3
Total M&I 562 28.1
Inferred 567 9.6
     

Notes:

  1. LCE is calculated using the Li:LCE factor = 5.322785 multiplied by the mass of Lithium
  2. Mineral Resources are not mineral reserves and do not have demonstrated economic viability. There is no certainty that all or any part of the mineral resource will be converted to mineral reserves.
  3. The Mineral Resource Estimate represented as LCE for Cauchari-Olaroz has an effective date of January 1, 2026, and it is expressed relative to the delineated resource area.
  4. The qualified person for the Mineral Resource Estimate is Mark King, PhD PGeo., FGC, a “qualified person” as defined in National Instrument 43-101, who is independent of the Company. The qualified person is not aware of any known legal, political, environmental or other risks that could materially affect the potential development of the Mineral Resources.
  5. No cut-off values have been applied to the resource estimate.
  6. Stage 2 economics are not based on Inferred Mineral Resources.

Next Steps

The Company intends to continue advancing Stage 2 through engineering, permitting and early development activities while progressing toward a future development decision. Key activities are expected to include:

  • Advance Early Works Strategy: Continue early development activities under existing permits, including production and exploration drilling, industrial water development and site preparation activities.
    • Continue detailed engineering and optimization of the Stage 2 expansion, incorporating operational learnings from the existing Cauchari-Olaroz operation.
  • Modular DLE Development: Progress project and engineering of the initial modular DLE facility, expected to produce approximately 10,000 tpa LCE.
  • Environmental Permitting: Advance the EIA for the full 45,000 tpa expansion.
  • Project Financing: Advance financing activities consistent with the Company’s strategy to fund Stage 2 through internally generated cash flow and project-level debt.

Non-IFRS Measures

Operating cash costs per tonne are non-IFRS measures or ratios and do not have a standardized meaning under IFRS and may not be comparable to similar financial measures used by other issuers.  The Company believes that this measure provides investors with an improved ability to evaluate the prospects of the Company and Stage 2.  As Stage 2 is not in production, operating cash cost may not be reconciled to the nearest comparable measures under IFRS and nor an equivalent historical non-IFRS measure for Stage 2.

Operating Cash Cost $ per tonne of LCE
Projected Operating Cash Cost – Stage 2 $5,0064
   

Scientific & Technical Information and Qualified Persons

The scientific and technical information in this news release has been reviewed and approved by the independent qualified persons (“QPs”) listed below, each of whom is a “qualified person” as defined in NI 43-101.

  • James Wang, P.E., Director, Golder.
  • Mark King, PhD. PGeo., FGC
  • David Burga, P. Geo

Report Filing

The Company will file a technical report prepared in accordance with NI 43-101with respect to the Scoping Study on SEDAR+ (http://www.sedarplus.ca and on the Company’s website (http://www.lithium-argentina.com) within 45 days of this news release.

For U.S. reporting purposes, the Company intends to furnish this news release on Form 6-K and to file a Technical Report Summary (TRS) prepared in accordance with Subpart 1300 of Regulation S-K. The TRS will be prepared by, or under the supervision of, a qualified person as defined in S-K 1300 and will summarize the material scientific and technical information supporting the Scoping Study.

__________________________

4 Operating cost is defined as the net direct cash cost, or simply the cost of production including the costs of mining, processing, transportation, marketing, and onsite administration.

ABOUT LITHIUM ARGENTINA

Lithium Argentina owns and actively manages significant interests in large-scale lithium assets, a key material used in the production of lithium-ion batteries, electric vehicles, and battery energy storage systems (BESS). The Company, in partnership with Ganfeng operates the Cauchari-Olaroz lithium brine operation in the Jujuy province of Argentina and is advancing PPG in the Salta province of Argentina. Lithium Argentina currently trades on the TSX and on the NYSE under the ticker “LAR”.

For further information contact:
Investor Relations
Telephone: +1 778-653-8092
Email: kelly.obrien@lithium-argentina.com
Website: http://www.lithium-argentina.com

FORWARD-LOOKING INFORMATION

This news release contains “forward-looking information” and “forward-looking statements” (which we refer to collectively as forward-looking information) under the provisions of applicable securities legislation. Forward-looking information can be identified by the use of words such as seek”, “anticipate”, “plan”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “predict”, “propose”, “potential”, “target”, “intend”, “could”, “might”, “should”, “believe”, “scheduled”, “implement” and similar words or expressions. All statements, other than statements of historical fact, are forward-looking information. Forward-looking information in this news release include, without limitation, information with respect to the following matters or the Company’s expectations relating to such matters:  the timing of the filing of the technical report for the Scoping Study and TRS; and the anticipated benefits therefrom; , including the involvement of third-party investors, the timing and filing of applicable permitting applications; the use and effects of DLE technology; the results of the Scoping Study, including, without limitation, expected project life, production, capital and operating costs, IRR, NPV and other economic and operating parameters of Stage 2 at Cauchari; mineral resource estimates; and the timing and amount of future production and expected capacity of production of Stage 2; anticipated costs of the Initial Phase, timing of approvals and authorizations thereforand the potential benefits derived therefrom;  expectations with respect to funding the Stage 2 expansion; the development strategy for Stage 2 and the Initial Phase; expected benefits of RIGI approval and possible multiple pathways to fund development and the actions outlined under “Next Steps”.

Forward-looking information may involve known and unknown risks, assumptions and uncertainties which may cause the Company’s actual results or performance to differ materially. This information reflects the Company’s current views with respect to future events and is necessarily based upon a number of assumptions that, while considered reasonable by the Company today, are inherently subject to significant uncertainties and contingences, and accordingly, the Company can give no assurance that these assumptions and expectations will prove to be correct. With respect to forward-looking information included in this news release, the Company has made assumptions regarding, among other things: current technological trends; the business relationship between the Company and Ganfeng; ability to fund its operations; the ability to operate in a safe and effective manner; uncertainties relating to obtaining and/or maintaining mining, exploration, development, environmental and other permits or approvals in Argentina; demand for lithium; impact of increasing competition in the lithium business, including the Company’s competitive position in the industry; general economic conditions; stability and support of legislative, regulatory and community environment in the jurisdiction where it operates; estimates of and changes to market prices for lithium and commodities; estimates costs for the project or operation; estimates of mineral resources and mineral reserves, including whether mineral resources will ever be developed into mineral reserves; reliability of technical data; and the ability to achieve full production; and accuracy of budget and estimates. Forward-looking information also involves known and unknown risks that may cause actual results to differ materially, these risks include, among others: risk inherent to studies such as the Scoping Study, which are subject to significant assumptions and a high degree of uncertainty; risk that the Company may not be able to obtain the anticipated benefits from the RIGI regime as anticipated, or at all; risk that the Company may not be able to fund or finance the development of Stage 2 and/or the Initial Phase as contemplated, or at all;  risk that the Company will not be able to implement DLE technology; the operations may not operate and produce as planned; cost overruns; market prices affecting development of the operation; risks associated with co-ownership arrangements; risks with ability to successfully secure adequate financing if necessary; risks to the growth of the lithium markets; lithium prices; inability to obtain any future required governmental permits and approvals and that operations may be limited by government-imposed limitations; technology risk; inability to achieve and manage expected growth; political risk associated with foreign operations, including co-ownership arrangements with foreign domiciled partners; emerging and developing market risks; operational risks; changes in government regulations; changes in environmental requirements; failure to obtain or maintain necessary licenses, permits or approvals; insurance risk; receipt and security of mineral property titles and mineral tenure risk; changes in project or operation parameters; uncertainties associated with estimating mineral resources and mineral reserves, including uncertainties regarding assumptions underlying such estimates; whether mineral resources will ever be converted into mineral reserves; opposition to the; geological or technical or processing problems; liabilities and risks; health and safety risks; unanticipated results; unpredictable weather; unanticipated delays; reduction in demand for lithium; inability to generate profitable operations; restrictive covenants in debt instruments; intellectual property risks; dependency on key personnel; currency and interest rate fluctuations; and volatility in general market and industry conditions. Additional risks, assumptions and other factors are set out in the Company’s management discussion analysis, most recent Annual Report on Form 20-F, and other disclosure documents copies of which are available on SEDAR+ at www.sedarplus.ca

Although the Company has attempted to identify important risks and assumptions, given the inherent uncertainties in such forward-looking information, there may be other factors that cause results to differ materially. Forward-looking information is made as of the date hereof and the Company does not intend, and expressly disclaims any obligation to, update or revise the forward-looking information contained in this news release, except as required by law. Accordingly, readers are cautioned not to place undue reliance on forward-looking information. 

BURLINGTON, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) — Progress Software (Nasdaq: PRGS), a member of the Russell 2000 Index and an AI infrastructure software leader, today announced its financial results for the fiscal third quarter ended on August 31, 2026.

The company’s earnings release and a supplemental slide presentation can be accessed via the Investor Events & Presentations link on the Progress Investor Relations webpage. Progress will host a conference call today at 5:00 p.m. ET to discuss its results and outlook.

Conference Call Details

  • A live webcast of the call will be available at this link.
  • To access the conference call by phone, use this link to retrieve dial-in details. Participants are encouraged to dial in 15 minutes before the scheduled start time.
  • A replay of the conference call and supporting materials will be available on the Progress Investor Relations webpage following the live event.

About Progress Software
Progress Software (Nasdaq: PRGS) provides the context and control organizations need to reliably extract value from AI—context drawn from an organization’s data, content and workflows, and control over the security, governance and cost of their AI initiatives. Learn how hundreds of thousands of businesses, powering the work of tens of millions of professionals worldwide, realize value from trusted, enterprise-ready AI at www.progress.com.

Progress is a trademark or registered trademark of Progress Software Corporation and/or its subsidiaries or affiliates in the U.S. and other countries. Any other names contained herein may be trademarks of their respective owners.  

Investor Contact: Press Contact:
Michael Micciche Jeff Young
Progress Software Progress Software
+1 781-850-8450 +1 781-280-4000
Investor-Relations@progress.com PR@progress.com


Source: Progress Software Corporation

FREMONT, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) — ACM Research, Inc. (“ACM”) (NASDAQ: ACMR), a leading supplier of wafer and panel processing solutions for semiconductor and advanced packaging applications, today announced management’s participation in the 18th Annual CEO Investor Summit 2026, being held Tuesday, October 13th, 2026 at the St. Regis Hotel in San Francisco, California.

The presentation material utilized during the CEO Investor Summit will be made accessible on the events page of the Company’s IR website at https://ir.acmr.com/news-events/events.

About the 18th Annual CEO Investor Summit 2026

The CEO Investor Summit is held annually each year during the SEMICON West industry trade show. Collectively hosted and funded by participating companies, the CEO Investor Summit features a “round-robin” format consisting of small group meetings with company management teams. During the event, investors and analysts will have the opportunity to meet with the majority of the 11 management teams during the small group meeting sessions and networking events.

The 11 management teams collectively hosting the 18th Annual CEO Investor Summit include: ACM Research (ACMR), Aehr Test Systems (AEHR), Alpha & Omega Semiconductor (AOSL), Cohu, Inc. (COHU), FormFactor (FORM), Ichor Systems (ICHR), InTEST Corporation (INTT), Kulicke & Soffa (KLIC), Photronics (PLAB), QuickLogic (QUIK), and SkyWater Technology, an IonQ company (IONQ). B Riley Securities, Jefferies and Stifel are sponsors of the conference.

Attendance at the CEO Investor Summit is by invitation only and is available solely to accredited investors and publishing research analysts. As space is limited, please RSVP early. Hosts reserve the right to limit attendance as necessary. Last day for registration is October 2, 2026.

RSVP Contacts for 18th Annual CEO Investor Summit 2026

To RSVP for the CEO Investor Summit, please visit the CEO Summit Events website or contact either of the event co-chairs:

Laura J. Guerrant-Oiye Claire E. McAdams
Phone: (808) 960-2642 Phone: (530) 265-9899
Email: lauraoiye@gmail.com Email: claire@headgatepartners.com
   

About ACM Research, Inc.

ACM develops, manufactures and sells semiconductor process equipment spanning cleaning, electroplating, stress-free polishing, vertical furnace processes, track, PECVD, and wafer- and panel-level packaging tools, enabling advanced and semi-critical semiconductor device manufacturing. ACM is committed to delivering customized, high-performance, cost-effective process solutions that semiconductor manufacturers can use in numerous manufacturing steps to improve productivity and product yield. For more information, visit www.acmr.com.

© ACM Research, Inc. ACM Research logo is a trademark of ACM Research, Inc. For convenience, these trademarks appear in this press release without ™ symbols, but that practice does not mean ACM will not assert, to the fullest extent under applicable law, its rights to such trademarks. All other trademarks are the property of their respective owners.

For investor and media inquiries, please contact:

In the United States: The Blueshirt Group
Steven C. Pelayo, CFA
+1 (360) 808-5154
steven@blueshirtgroup.co
   
In China: The Blueshirt Group Asia
Gary Dvorchak, CFA
gary@blueshirtgroup.co

New Data Analysis from Phase 2a Clinical Trial in Alzheimer’s Disease (AD) Indicating That Laromestrocel Treatment May Reduce Neuroinflammation in the Brain, A Core Driver of AD Pathogenesis, Published on medRxiv

MIAMI, Sept. 30, 2026 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will participate in three upcoming Longevity/Aging investment conferences.

13th Aging Research and Drug Discovery Meeting (ARDD) to be held October 1-3, 2026 in Boston

Abundance Longevity Trip to be held October 7-11, 2026 (virtual participation)

Longevity Partnering Forum to be held October 19-20, 2026 in South San Francisco

Longevity and Aging-Related Frailty
The Company intends to pursue funding sources and other potential revenue opportunities to advance laromestrocel in longevity and Aging-related Frailty. Results from a Phase 2b clinical trial demonstrated that intravenous laromestrocel improved the physical condition of patients with age-related clinical frailty after nine months, compared to placebo. These results were published in Cell Stem Cell in February 2026. Further, based on these clinical trial results, Longeveron announced in August 2026 that it was selected from over 600 worldwide applicants to advance to the final phase of the XPRIZE Healthspan competition as a Milestone 2 Awardee team. Longeveron received the $1,000,000 Milestone 2 Award to be used towards the future competition clinical trial in accordance with the XPRIZE competition rules, with the opportunity to compete for the XPRIZE Grand Prize of up to $81 million.

New Analysis of Laromestrocel Phase 2a Data in Alzheimer’s Disease Published on medRxiv
The Company has recently published a new manuscript as a pre-print in medRxiv, detailing post-hoc exploratory analysis from the Company’s Phase 2a randomized CLEAR MIND study (NCT05233774; n=49) in AD that indicated laromestrocel treatment may reduce neuroinflammation in the brain—a core driver of AD pathogenesis, using free water MRI imaging.

This is a preprint and has not yet completed peer review. Laromestrocel is an investigational product and has not been approved by the FDA or any other regulatory agency.

Read the full preprint: https://www.medrxiv.org/content/10.64898/2026.09.16.26363132v1

Key findings:

  • Laromestrocel inhibited the progression of neuroinflammation, with the strongest effects in regions at the core of Alzheimer’s pathology, including the left hippocampus (p<0.001 in both the 25M and 100M cell dose groups), as well as the temporal and parietal cortex.
  • Reduced neuroinflammation correlated with less brain atrophy and with improved clinical scores, particularly cognition as measured by MoCA.
  • Treated participants showed lower plasma neurogranin, consistent with reduced synaptic loss.
  • Blood biomarker analyses point to a convergent, multimodal mechanism of action involving peripheral immune engagement.

Together, these results support the hypothesis that laromestrocel’s potential anti-inflammatory effects may help protect brain tissue and function in Alzheimer’s disease. If confirmed, durable anti-inflammatory effects may also be useful in combatting chronic inflammation in aging, or “inflammaging”.

These new results follow publication of main CLEAR MIND trial results in Nature Medicine in 2025. https://www.nature.com/articles/s41591-025-03559-0

About laromestrocel (Lomecel-B®)
Laromestrocel is a living cell product made from specialized cells isolated from the bone marrow of young, healthy adult donors. These specialized cells, known as mesenchymal stem cells (MSCs), are essential to the human endogenous biological repair mechanism. MSCs have the potential to perform a number of complex functions in the body and possibly support tissue repair and regenerative signaling pathways. They also may respond to sites of injury or disease and may secrete bioactive factors that are immunomodulatory and regenerative. We believe laromestrocel MSCs may have multiple potential mechanisms of action that may lead to anti-inflammatory, pro-vascular regenerative responses, and therefore may have broad application for a range of rare and aging related diseases.

About Longeveron Inc.
Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is laromestrocel (Lomecel-B®), an allogeneic mesenchymal stem cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. We believe laromestrocel has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is pursuing four pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, Pediatric Dilated Cardiomyopathy (DCM) and Aging-related Frailty. Laromestrocel development programs have received five distinct and important FDA designations: for the HLHS program – Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program – Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn, X, and Instagram.

Forward-Looking Statements
Certain statements in this press release that are not historical facts are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which reflect management’s current expectations, assumptions, and estimates of future operations, performance and economic conditions, and involve known and unknown risks, uncertainties, and other important factors that could cause actual results, performance, or achievements to differ materially from those anticipated, expressed, or implied by the statements made herein. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate, including our ability to pursue funding sources and potential revenue opportunities to advance laromestrocel in longevity and Aging-related frailty; our expectations regarding the review and exploration of all options and their potential impact on shareholder value; our ability to engage an investment bank or other strategic advisor; the continued listing of our Class A common stock on Nasdaq; our expectations regarding the future of the Company’s operations, including our clinical, development and commercialization activities; our plans to implement cash conservation measures to reduce operating expenses; and other statements regarding future events. Forward-looking statements are generally identifiable by the use of forward-looking terminology such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expects,” “intend,” “looks to,” “may,” “on condition,” “plan,” “potential,” “predict,” “preliminary,” “project,” “see,” “should,” “target,” “will,” “would,” or the negative thereof or comparable terminology, although not all forward-looking statements contain these words, or by discussion of strategy or goals or other future events, circumstances, or effects. Additional factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statements in this release include, but are not limited to, the risk that the exploration of strategic options may not result in any definitive transaction or enhance shareholder value or may create uncertainty that may adversely affect our business, financial condition, results of operations, or shareholder and investor perception; the ability of our clinical trials to demonstrate safety and efficacy of our investigational product candidates, and other positive results; our ability to successfully transition toward a more capital-efficient, asset-light operating model; our ability to secure one or more strategic licensing partnerships for laromestrocel in our development programs; our ability to reach alignment with the FDA and other regulatory authorities on a potential path toward regulatory approval; the availability of evidence from our ongoing and future preclinical studies and clinical trials sufficient to support the Company filing a BLA for the investigational product candidate for one or more indications; the timing and focus of our ongoing and future preclinical studies and clinical trials, and the reporting of data from those studies and trials; market and other conditions, our cash position and need to raise additional capital, the difficulties we may face in obtaining access to capital, and the dilutive impact it may have on our investors; our financial performance, and ability to continue as a going concern; the period over which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements; the size of the market opportunity for certain of our investigational product candidates, including our estimates of the number of patients who suffer from the diseases we are targeting; our ability to scale production and commercialize the investigational product candidate for certain indications; the success of competing therapies that are or may become available; the beneficial characteristics, safety, efficacy and therapeutic effects of our investigational product candidates; our ability to obtain and maintain regulatory approval of our investigational product candidates in the U.S. and other jurisdictions; our plans relating to the further development of our investigational product candidates, including additional disease states or indications we may pursue; our plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available and our ability to avoid infringing the intellectual property rights of others; the need to hire additional personnel and our ability to attract and retain such personnel; and our estimates regarding expenses, future revenue, capital requirements and needs for additional financing.

Further information relating to factors that may impact the Company’s results and forward-looking statements are disclosed in the Company’s filings with the Securities and Exchange Commission, including Longeveron’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission on March 17, 2026, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. The Company operates in a highly competitive and rapidly changing environment; therefore, new factors may arise, and it is not possible for the Company’s management to predict all such factors that may arise nor assess the impact of such factors or the extent to which any individual factor or combination thereof, may cause results to differ materially from those contained in any forward-looking statements. The forward-looking statements contained in this press release are made as of the date of this press release based on information available as of the date of this press release, are inherently uncertain, and the Company disclaims any intention or obligation, other than imposed by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Investor and Media Contact:
Derek Cole
Investor Relations Advisory Solutions 
derek.cole@iradvisory.com

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.